Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections

Kura Oncology, Inc.

2023-Q2 EPS reported -$1.03

Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).
Cash, equivalents & investments $477M at June 30, 2023; includes $93.6M net from June offering; runway to mid-2026.
Ziftomenib in NPM1-mutant AML: CR rate 35% at 600 mg RP2D; registration-directed trial (85 pts) enrollment ahead of projections.
Combination study KOMET-007 (ziftomenib + ven/aza or 7+3) now dosing patients; preliminary data expected Q4 2023 or Q1 2024.
Next-gen FTI KO-2806 Phase 1 FIT-001 trial to begin dosing in H2 2023; tipifarnib+alpelisib in HNSCC at highest planned dose cohort.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Kura Oncology, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2023 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037994

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.